首页>
外国专利>
Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with Clostridium difficile disease
Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with Clostridium difficile disease
展开▼
机译:粪便乳铁蛋白是确定艰难梭菌 I>病患者疾病严重程度和治疗感染的生物标志物
展开▼
页面导航
摘要
著录项
相似文献
摘要
Clostridium difficile disease involves a range of clinical presentations ranging from mild to self-limiting diarrhea to life-threatening pseudomembranous colitis and megacolon. Cases of C. difficile are treated differently depending on severity of disease. Mild and moderate cases may be treated with metronidazole while moderate-to-severe and relapsing cases are often treated with vancomycin or fidaxomicin. The presence of C. difficile disease is detected using a biomarker panel that includes C. difficile antigen (GDH), toxins A and B, and fecal lactoferrin. In patients suspected of C. difficile disease, if GDH is detected indicating the presence of C. difficile, and then toxins A and/or B are detected to indicate toxigenic C. difficile and support a diagnosis of C. difficile-associated disease, fecal lactoferrin concentrations are measured to determine severity of the disease by indicating the amount of intestinal inflammation.
展开▼